ICVX Insider Trading Activity and SEC Form 4 Filings
ICVX insider trading summary
No open-market insider purchases or sales of Icosavax, Inc. (ICVX) have been reported on SEC Form 4 in the past 12 months.
Latest ICVX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 1, 2024 | Adam K. Simpson | Chief Executive Officer | Sell | $229K (15,000 @ $15.29) |
| Jan 2, 2024 | Adam K. Simpson | Chief Executive Officer | Sell | $235K (15,000 @ $15.67) |
| Dec 21, 2023 | Adam K. Simpson | Chief Executive Officer | Sell | $617K (40,000 @ $15.43) |
| Dec 21, 2023 | Adam K. Simpson | Chief Executive Officer | Sell | $772K (50,000 @ $15.44) |
| Dec 20, 2023 | Thomas Joseph Russo | Chief Financial Officer | Sell | $69K (4,430 @ $15.46) |
| Dec 20, 2023 | Niranjan Kanesa-thasan | Chief Medical Officer | Sell | $184K (11,884 @ $15.46) |
| Dec 20, 2023 | Thomas Joseph Russo | Chief Financial Officer | Sell | $166K (10,753 @ $15.46) |
| Dec 20, 2023 | Adam K. Simpson | Chief Executive Officer | Sell | $962K (62,205 @ $15.46) |
| Dec 20, 2023 | Cassia Cearley | Chief Business Officer | Sell | $123K (7,934 @ $15.46) |
| Dec 13, 2023 | Cassia Cearley | Chief Business Officer | Sell | $140K (8,759 @ $16.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.